157 related articles for article (PubMed ID: 11394506)
1. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
2. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
7. Update on therapeutic options in Waldenström macroglobulinemia.
Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
[TBL] [Abstract][Full Text] [Related]
8. Waldenström macroglobulinemia.
Ghobrial IM; Witzig TE
Curr Treat Options Oncol; 2004 Jun; 5(3):239-47. PubMed ID: 15115652
[TBL] [Abstract][Full Text] [Related]
9. Novel agents in Waldenstrom Macroglobulinemia.
Sacco A; Leleu X; Rossi G; Ghobrial IM; Roccaro AM
Open J Hematol; 2010 May; 1():. PubMed ID: 22844582
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
11. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
12. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
Izutsu K; Kato H; Sekiguchi N; Fujisaki T; Kawakita T; Obara N; Matsue K; Nishimoto M; Hatayama T; Inagaki M; Fujikawa E
Int J Hematol; 2024 Apr; ():. PubMed ID: 38597986
[TBL] [Abstract][Full Text] [Related]
13. Relapsed Waldenstrom's Macroglobulinemia and Therapy-Related Myelodysplastic Syndrome with Complex Cytogenetics: A Treatment Dilemma.
Kalantri S; Singh I; Yang L; Abuelgasim KA
Case Rep Oncol; 2023; 16(1):351-356. PubMed ID: 37384207
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Approaches for Waldenstrom Macroglobulinemia.
Stedman J; Roccaro A; Leleu X; Ghobrial IM
Drugs Future; 2010 Jan; 35(1):53-58. PubMed ID: 21869855
[TBL] [Abstract][Full Text] [Related]
15. Novel agents in Waldenström macroglobulinemia.
Issa GC; Ghobrial IM; Roccaro AM
Clin Investig (Lond); 2011; 1(6):815-824. PubMed ID: 22034589
[TBL] [Abstract][Full Text] [Related]
16. Long-term Survival in a Patient With Transformation of Waldenström's Macroglobulinemia into DLBCL.
Solia E; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
Cancer Diagn Progn; 2024; 4(1):77-80. PubMed ID: 38173665
[TBL] [Abstract][Full Text] [Related]
17. Hematologic secondary malignancies among 102 Chinese patients with Waldenstrom's macroglobulinemia: a single-center case experience and literature review.
Wang L; Xi C; Huang Y; Xu H; Miao Y; Cheng Y
Front Oncol; 2023; 13():1280033. PubMed ID: 38090491
[TBL] [Abstract][Full Text] [Related]
18. Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline.
Amaador K; Kersten MJ; Minnema MC; Vos JMI
Hemasphere; 2022 Jul; 6(7):e746. PubMed ID: 35813102
[TBL] [Abstract][Full Text] [Related]
19. Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.
Chen J; Jia MN; Cai H; Li ZP; Li J; Zhou DB; Cao XX
Ann Hematol; 2024 Mar; ():. PubMed ID: 38448788
[TBL] [Abstract][Full Text] [Related]
20. Waldenstrom's Macroglobulinemia: An Update.
Mazzucchelli M; Frustaci AM; Deodato M; Cairoli R; Tedeschi A
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018004. PubMed ID: 29326801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
